ACE Inhibitors: Clinical Pharmacology, CKD Benefits, Monitoring and Contraindications

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling.

Overview

Angiotensin-converting enzyme (ACE) inhibitors decrease formation of angiotensin II and increase bradykinin, promoting vasodilation and reducing aldosterone secretion. Indications include hypertension, selected heart-failure regimens, post-MI LV dysfunction and albuminuric CKD. Medication choice should follow comorbidities and tolerance rather than automatic interchangeability [1–3].

Correct chemical classification

  • Sulfhydryl-containing: captopril.
  • Dicarboxylate-containing: enalapril, lisinopril, ramipril, perindopril and several others.
  • Phosphinate-containing: fosinopril.

The former text’s ‘thienopyridine’ classification was incorrect. Most ACE inhibitors are prodrugs activated by esterases; captopril and lisinopril are active as administered. Chemical grouping does not replace pharmacokinetic and indication-specific prescribing [1].

Mechanisms and pharmacokinetics

ACE is a dipeptidyl carboxypeptidase that converts angiotensin I to angiotensin II and degrades bradykinin. Inhibition lowers angiotensin-dependent vasoconstriction, aldosterone-driven potassium excretion and maladaptive cardiac remodeling. Enalapril is converted to enalaprilat; ramipril to ramiprilat. Most agents rely substantially on renal elimination, though fosinopril has mixed hepatic and renal clearance. Kidney-function changes alter exposure and monitoring needs [1].

Clinical benefits

ACE inhibition lowers BP and improves outcomes in appropriately selected HFrEF and post-MI patients. KDIGO 2024 recommends ACEi or ARB for albuminuric CKD in specified groups, including diabetes with A2/A3 albuminuria; use a maximally tolerated approved dose when appropriate. Monitor creatinine and potassium within 2–4 weeks after initiation or dose change and evaluate a creatinine increase exceeding 30% [2,3].

Adverse effects

Dry cough results partly from bradykinin accumulation. Angioedema can be life-threatening; ACE inhibitors should not be restarted after ACE-inhibitor-associated angioedema. Other harms include hyperkalemia, hypotension and acute kidney injury in susceptible patients. Monitor carefully with dehydration, NSAIDs, kidney disease and potassium-raising drugs. A mild expected creatinine rise is not automatically a reason to discontinue [1,2].

Interactions and contraindications

ACE inhibitors are contraindicated in pregnancy because of fetal toxicity. Do not combine routinely with ARBs or aliskiren, especially in CKD; concomitant potassium-sparing diuretics or potassium supplements require careful monitoring. ACE inhibition must not overlap with sacubitril/valsartan; a 36-hour washout is required when switching between an ACE inhibitor and sacubitril/valsartan because of angioedema risk. A history of hereditary or prior ACE inhibitor–associated angioedema warrants strict precautions [1–3].

Clinical takeaways

Start at an appropriate dose, assess kidney function, potassium and blood pressure, and reassess symptoms. If cough occurs, an ARB may be considered when appropriate; previous severe ACE-related angioedema needs specialist safety evaluation rather than automatic substitution [1].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. KDIGO. KDIGO 2024 clinical practice guideline for evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117–S314. Available from: https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf
  3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for management of heart failure. Available from: https://www.jacc.org/doi/full/10.1016/j.jacc.2021.12.012
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *